DMSO in the Treatment of Dupuytren's Contracturel: A Therapeutic Experiment

Vuopala, U.; Kaipainen, W. J.

doi:10.3109/rhe1.1971.17.issue-1-4.09

Cited by 20 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A variety of non-surgical interventions, including injection of steroids [12] or gamma-interferon [13], use of creams based on vitamin E [14], dimethyl sulphoxides [15], and ultrasound therapy [16] etc. yield limited benefits.…”

Section: Introductionmentioning

confidence: 99%

Fibroblasts from phenotypically normal palmar fascia exhibit molecular profiles highly similar to fibroblasts from active disease in Dupuytren's Contracture

et al. 2012

View full text Add to dashboard Cite

BackgroundDupuytren's contracture (DC) is a fibroproliferative disorder characterized by the progressive development of a scar-like collagen-rich cord that affects the palmar fascia of the hand and leads to digital flexion contractures. DC is most commonly treated by surgical resection of the diseased tissue, but has a high reported recurrence rate ranging from 27% to 80%. We sought to determine if the transcriptomic profiles of fibroblasts derived from DC-affected palmar fascia, adjacent phenotypically normal palmar fascia, and non-DC palmar fascial tissues might provide mechanistic clues to understanding the puzzle of disease predisposition and recurrence in DC.MethodsTo achieve this, total RNA was obtained from fibroblasts derived from primary DC-affected palmar fascia, patient-matched unaffected palmar fascia, and palmar fascia from non-DC patients undergoing carpal tunnel release (6 patients in each group). These cells were grown on a type-1 collagen substrate (to better mimic their in vivo environments). Microarray analyses were subsequently performed using Illumina BeadChip arrays to compare the transcriptomic profiles of these three cell populations. Data were analyzed using Significance Analysis of Microarrays (SAM v3.02), hierarchical clustering, concordance mapping and Venn diagram.ResultsWe found that the transcriptomic profiles of DC-disease fibroblasts and fibroblasts from unaffected fascia of DC patients exhibited a much greater overlap than fibroblasts derived from the palmar fascia of patients undergoing carpal tunnel release. Quantitative real time RT-PCR confirmed the differential expression of select genes validating the microarray data analyses. These data are consistent with the hypothesis that predisposition and recurrence in DC may stem, at least in part, from intrinsic similarities in the basal gene expression of diseased and phenotypically unaffected palmar fascia fibroblasts. These data also demonstrate that a collagen-rich environment differentially alters gene expression in these cells. In addition, Ingenuity pathway analysis of the specific biological pathways that differentiate DC-derived cells from carpal tunnel-derived cells has identified the potential involvement of microRNAs in this fibroproliferative disorder.ConclusionsThese data show that the transcriptomic profiles of DC-disease fibroblasts and fibroblasts from unaffected palmar fascia in DC patients are highly similar, and differ significantly from the transcriptomic profiles of fibroblasts from the palmar fascia of patients undergoing carpal tunnel release.

show abstract

Section: Introductionmentioning

confidence: 99%

Fibroblasts from phenotypically normal palmar fascia exhibit molecular profiles highly similar to fibroblasts from active disease in Dupuytren's Contracture

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Gastrointestinal adverse reactions were reported in 61 studies. Of these, 10 studies were randomized controlled trials 16, 30, 33, 55, 57, 59, 67, 79, 93, 95 , 49 were cohort studies 2, 4, 7, 9, 18, 19, 23, 25– 27, 29, 35, 38– 43, 45, 46, 48, 50– 54, 58, 60, 66, 68, 69, 71, 73, 83, 85– 88, 90, 94, 97, 98, 101, 104, 105, 112, 113, 115, 118 , and 2 were case series 84, 109 . Most studies reported the number of patients experiencing an adverse reaction ( Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…Halitosis was reported in 29 studies 4, 9, 16, 19, 29, 30, 35, 42, 43, 45, 50, 52, 55, 57, 58, 66– 68, 79, 83, 85, 88, 94, 95, 97, 98, 109, 112, 113 . In five studies, patients discontinued treatment due to halitosis 9, 45, 83, 94 .…”

Section: Resultsmentioning

confidence: 99%

Adverse reactions of dimethyl sulfoxide in humans: a systematic review

et al. 2019

View full text Add to dashboard Cite

Background: Dimethyl sulfoxide (DMSO) has been used for medical treatment and as a pharmacological agent in humans since the 1960s. Today, DMSO is used mostly for cryopreservation of stem cells, treatment of interstitial cystitis, and as a penetrating vehicle for various drugs. Many adverse reactions have been described in relation to the use of DMSO, but to our knowledge, no overview of the existing literature has been made. Our aim was to conduct a systematic review describing the adverse reactions observed in humans in relation to the use of DMSO. Methods: This systematic review was reported according to the PRISMA-harms (Preferred Reporting Items for Systematic reviews and Meta-Analysis) guidelines. The primary outcome was any adverse reactions occurring in humans in relation to the use of DMSO. We included all original studies that reported adverse events due to the administration of DMSO, and that had a population of five or more. Results: We included a total of 109 studies. Gastrointestinal and skin reactions were the commonest reported adverse reactions to DMSO. Most reactions were transient without need for intervention. A relationship between the dose of DMSO given and the occurrence of adverse reactions was seen. Conclusions: DMSO may cause a variety of adverse reactions that are mostly transient and mild. The dose of DMSO plays an important role in the occurrence of adverse reactions. DMSO seems to be safe to use in small doses. Registration: PROSPERO CRD42018096117.

show abstract

“…n Other methods Various agents have been tried without significant improvement in DD digital contracture. These include IFN-g [52], dimethyl sulfoxide [53], vitamin E [54], methylhydrazine [55], allopurinol [56], ultrasonic therapy [57], physical therapy [58] and calcium channel blockers [59]. Steroid injection has shown some success to date on nodule resolution [60,61] and injectable collagenase C. histolyticum on cord dissolution.…”

Section: Nonoperative Treatmentmentioning

confidence: 99%